PMI’s net revenues were $32.8 billion for the nine months ended September 30, 2026, up 8.2%, and $11.4 billion for the three months ended September 30, 2026, up 5.5%. Diluted EPS was $5.48 and $2.12, respectively.
PM · Philip Morris International Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Philip Morris International reported Q3 organic net revenue growth of plus 7.1% to $11.4 billion, adjusted diluted EPS of $2.36, and ICOS adjusted IMS growth of plus 7.1%. Full-year organic net revenue growth is forecast at plus 5% to plus 7%.
Philip Morris International reported Q3 operating income up 14.1% and adjusted diluted EPS of $2.36, up 5.4%; it forecast 2026 adjusted diluted EPS growth of 9.9% to 11.9% and raised the dividend 8.8% to $1.60 per share.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 21, 2026TL;DR. PMI delivered record Q3 revenue and operating income, with strong IQOS, ZYN, VEEV and combustible performance, and forecasts 5% to 7% full-year organic revenue growth. Risks include guidance leaning toward the lower half of its ranges, near-zero expected U.S. Q4 profitability, geopolitical cost pressure, declining cigarette volumes and a 41.1% decline in year-to-date U.S. adjusted OCI.
- + Q3 net revenues rose 7.1% organically to $11.4 billion and operating income rose 10.5% organically, setting records for quarterly net revenue, gross profit and operating income.
- + IQOS HTU adjusted IMS grew 7.1%, or 10% excluding Japan and Poland, and shipments reached the high end of prior expectations.
- + VEEV quarterly shipments increased 61.6%, extending the brand's European leadership and producing promising results in newer markets.
- + U.S. ZYN shipments grew 4.2% to 3.2 billion pouches, while segment net revenues rose 22.7% and gross profit rose 24.2%.
- + International combustibles delivered 7.8% organic revenue growth and 9.8% organic gross-profit growth, while Marlboro reached a record 11.4% category share.
- + Full-year organic net revenue growth is forecast at 5% to 7%, with greater likelihood of landing in the middle or upper half of the range.
- − Management now expects full-year operating-income and EPS growth to land in the midpoint or lower half of their respective guidance ranges.
- − Q4 U.S. adjusted OCI is expected around zero or slightly negative as elevated investment and the 20-pouch transition reduce revenue per pouch by approximately 25%.
- − Geopolitical conflicts are expected to reduce full-year adjusted diluted EPS growth by approximately one percentage point.
- − Reported Q3 diluted EPS declined 4.9% to $2.12, primarily because of the fair-value adjustment for equity-security investments.
- − Cigarette volumes declined 1.2% year to date, and full-year cigarette volume is now expected to decline by a similar level.
- − U.S. adjusted OCI declined 41.1% organically to $550 million for the first nine months.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted IMS growth outside Europe and Japan | 12.7% | third quarter filing | — |
| annualized dividend rate | 6.4 | the third quarter of 2026 filing | — |
| AveragePrice PaidPer Share | $182.79 | For the Quarter Ended September 30, 2026 filing | — |
| Cigarettes | 158B | For the Three Months Ended September 30, 2026 filing | — |
|
|
|||
| Depreciation and amortization expense: International Combustibles | 67M | the three months ended September 30, 2026 filing | — |
| Depreciation and amortization expense: International Smoke-Free | 93M | the three months ended September 30, 2026 filing | — |
| Depreciation and amortization expense: Other | 324M | the three months ended September 30, 2026 filing | — |
| Depreciation and amortization expense: U.S. | 27M | the three months ended September 30, 2026 filing | — |
| Dutch pension plan buy-out loss | $74M | the third quarter of 2026 filing | — |
| E-vapor | 1.4B | For the Three Months Ended September 30, 2026 filing | — |
|
|
|||
| HTU | 41.5B | For the Three Months Ended September 30, 2026 filing | — |
|
|
|||
| HTU adjusted IMS growth | 7.1% | third quarter filing | — |
| increase in the quarterly dividend | 8.8% | the third quarter of 2026 filing | — |
| International Combustibles cigarette category volume share | 25.9% | third quarter filing | — |
|
|
|||
| International Smoke-Free shipment volume | 44.5B | third quarter filing | — |
|
|
|||
| IQOS category share | 68% | third quarter filing | — |
| IQOS HTU adjusted IMS growth in Europe | 6% | third quarter filing | — |
| IQOS HTU adjusted market share | 11.6% | third quarter filing | — |
| IQOS shipment volume | 41.5B | third quarter filing | — |
| Marlboro category share | 11.4% | third quarter filing | — |
|
|
|||
| Modern oral volume growth | 20.6% | third quarter filing | — |
|
|
|||
| Total depreciation and amortization expense | 511M | the three months ended September 30, 2026 filing | — |
| Total depreciation and amortization expense by segment | 187M | the three months ended September 30, 2026 filing | — |
| Total Number of Shares Repurchased | 10,304 | For the Quarter Ended September 30, 2026 filing | — |
| total pre-tax restructuring charges | 4M | three months ended September 30, 2026 filing | — |
| U.S. oral smoke-free products shipment volume | 3.7B | third quarter filing | — |
|
|
|||
| U.S. smoke-free product shipment volume growth | 2.3% | third quarter filing | — |
| VEEV quarterly shipments growth | 61.6% | third quarter filing | — |
|
|
|||
| ZYN shipment growth | 4.2% | third quarter filing | — |
| ZYN shipments | 3.2B | third quarter filing | — |
|
|
|||
| cigarette shipment volume in the International Combustibles segment | 156.9B | the second quarter filing | — |
| Estimated industry volume growth (excluding China and the U.S.) for cigarettes and HTUs | 0.8% | the three months ended June 30, 2026 filing | — |
| HTU adjusted IMS volume growth | 5.1% | the three months ended June 30, 2026 filing | — |
| Modern oral volume | 0.6B | the three months ended June 30, 2026 filing | — |
| Oral SFP shipment volume | 5.1B | the three months ended June 30, 2026 filing | — |
| restructuring charges | $6M | For the Three Months Ended June 30, 2026 filing | — |
| Smoke-Free Products shipment volume | 48.2B | the three months ended June 30, 2026 filing | — |
| Total shipment volume | 205.2B | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Tobacco — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PM
this stock
Philip Morris International Inc.
|
$300.40B | +20.2% | +7.3% | 28.2 | 1.0% |
|
MO
Altria Group, Inc.
|
$126.85B | +32.3% | -3.1% | 15.7 | 2.4% |
|
BTI
British American Tobacco p.l.c.
|
$125.62B | +3.3% | — | — | 0.3% |
|
RLX
RLX Technology Inc.
|
$1.78B | -37.3% | +50.3% | — | 0.7% |
|
AIIR
AIR Global PLC
|
$1.14B | -40.8% | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 23, 2026
- This year
- 33
PMI’s net revenues were $32.8 billion for the nine months ended September 30, 2026, up 8.2%, and $11.4 billion for the three months ended September 30, 2026, up 5.5%. Diluted EPS was $5.48 and $2.12, respectively.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PM | -1.8% | -2.4% | +8.7% | -7.7% | +20.2% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +2.1% | +3.2% | +12.1% | -4.3% | +13.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.